The APPLE's core question-upfront osimertinib versus the sequential approach for <i>EGFR</i> mutated non-small cell lung cancer.

ABSTRACT:

SUBMITTER: Wei JQ 

PROVIDER: S-EPMC11898351 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature